Investors should watch these companies come July 18th.
Positive subscription trends and less downside risk this year have the company well positioned, Mizuho says.
Individual state investigations of opioid marketing practices has lead to a multistate investigation of the prescription painkiller industry.
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.